Given that inhibitory activity of PD-1H in T cells and ablation of PD-1H may improve the efficacy of T cell–mediated antitumor immunotherapies, we further extended this approach to humanized mouse models with adoptive transfer of CAR-engineered human T cells against human cancer. This evidence concerns the gene VSIR and cancer.